(Q39732749)

14 September 2017

1 reference

title

Etiopathogenesis, clinical manifestations, and management of canine calcium oxalate urolithiasis (English)

1 reference

14 September 2017

1 reference

1 reference

Osborne CA

1

1 reference

14 September 2017

Poffenbarger EM

2

1 reference

14 September 2017

Klausner JS

3

1 reference

14 September 2017

Johnston SD

4

1 reference

14 September 2017

Griffith DP

5

1 reference

14 September 2017

publication date

1 January 1986

1 reference

Veterinary Clinics of North America: Small Animal Practice

14 September 2017

published in

1 reference

14 September 2017

volume

16

1 reference

14 September 2017

issue

1

1 reference

14 September 2017

page(s)

133-170

1 reference

Methylene blue as an inhibitor of stone formation

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Renal oxalate excretion following oral oxalate loads in patients with ileal disease and with renal and absorptive hypercalciurias

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Effect of calcium restriction on renal excretion of oxalate and the probability of stones in the various pathophysiological groups with calcium stones

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Critical role of oxalate restriction in association with calcium restriction to decrease the probability of being a stone former: insufficient effect in idiopathic hypercalciuria

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Theoretical and clinical importance of the differentiation between the two types of calcium oxalate hydrate

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

On the pathogenesis of so-called idiopathic hypercalciuria

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Oral Administration of Methylene Blue to Patients with Renal Calculi

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

The role of dietary sodium on renal excretion and intestinal absorption of calcium and on vitamin D metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Letter: Vitamin-C-induced hyperoxaluria

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Urinary oxalate and vitamin-C supplements.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Bioavailability of oxalate in foods

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Pathophysiological Studies in Idiopathic Hypercalciuria: Use of an Oral Calcium Tolerance Test to Characterize Distinctive Hypercalciuric Subgroups*

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Evidence for disordered control of 1,25-dihydroxyvitamin D production in absorptive hypercalciuria.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Treated and untreated recurrent calcium nephrolithiasis in patients with idiopathic hypercalciuria, hyperuricosuria, or no metabolic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Evidence for secondary hyperparathyroidism in idiopathic hypercalciuria

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Metolazone therapy of active calcium nephrolithiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Inhibition of Calcium Oxalate Dihydrate Crystallization by Chemical Modifiers: I. Pyrophosphate and Methylene Blue

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

The paradox of inhibition and enhancement of the formation of urinary stones

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

The inhibitory effect of pyrophosphate on calcium oxalate precipitation and its relation to urolithiasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Vitamin B6 deficiency and oxalate nephrocalcinosis in the cat

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Urolithiasis update: biophysical and radiologic advances enhance antistone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Protective effects of heparin and other sulfated glycosaminoglycans on crystal adhesion to injured urothelium

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Nephrolithiasis in premature infants

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Nephrolithiasis in infants: association with chronic furosemide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Change in inhibitory potential in urine of hyperuricosuric calcium oxalate stone formers effected by allopurinol and orthophosphates

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Dietary NaCl loads promote calciuria and bone loss in adult oophorectomized rats consuming a low calcium diet

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

The protective effect of heparin in experimental bladder infection

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Hyperoxaluria and recurrent stone formation apparently cured by short courses of pyridoxine.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Effects of magnesium hydroxide in renal stone disease

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Biochemical and clinical effects of the prophylactic treatment of renal calcium stones with magnesium hydroxide

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

The role of 1 alpha, 25-dihydroxyvitamin D in the mediation of intestinal hyperabsorption of calcium in primary hyperparathyroidism and absorptive hypercalciuria

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Crystal retention by injured urothelium of the rat urinary bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Clinical manifestations of calcium oxalate monohydrate and dihydrate urolithiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Urinary Calcium Excretion in Human Beings

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Calcium oxalate dihydrate formation in urine

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Pentosan Polysulfate As An Inhibitor of Calcium Oxalate Crystal Growth

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Role of serum Ca, parathyroid hormone, and NaCl infusion on renal Ca and Na clearances

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Renal handling of uric acid in patients with recurrent calcium nephrolithiasis and hyperuricosuria

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Oxalate metabolism and renal calculi

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Urinary citrate excretion in patients with renal calculi

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

The lack of effect of methylene blue on struvite crystal formation.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Pathogenesis and clinical course of mixed calcium oxalate and uric acid nephrolithiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Idiopathic hypercalciuria in children: prevalence and metabolic characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Importance of dietary sodium in the hypercalciuria syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Vitamin D status in urinary calcium stone formation

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Use of potassium citrate as potassium supplement during thiazide therapy of calcium nephrolithiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Rice Bran Treatment for Patients with Hypercalciuric Stones: Experimental and Clinical Studies

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

The renal lesions of electrolyte imbalance. IV. The intranephronic calculosis of experimental magnesium depletion

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Medical management of nephrolithiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Effect of oral purine load and allopurinol on the crystallization of calcium salts in urine of patients with hyperuricosuric calcium urolithiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Evidence justifying a high fluid intake in treatment of nephrolithiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Augmentation of renal citrate excretion by oral potassium citrate administration: time course, dose frequency schedule, and dose-response relationship

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Dietary management of idiopathic calcium urolithiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Bladder-Surface Glycosaminoglycans: An Efficient Mechanism of Environmental Adaptation

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Magnesium oxide-pyridoxine therapy for recurrent calcium oxalate calculi

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

The evaluation of some biochemical parameters in pyridoxine-treated calcium oxalate renal stone formers

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

The Effect of High Animal Protein Intake on the Risk of Calcium Stone-Formation in the Urinary Tract

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Tamm-Horsfall mucoproteins promote calcium oxalate crystal formation in urine: quantitative studies

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Hypocitraturia in calcium nephrolithiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Effects of magnesium deficiency on intratubular calcium oxalate formation and crystalluria in hyperoxaluric rats

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistries and crystallization of stone-forming salts

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Urinary oxalate excretion after large intakes of ascorbic acid in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Crystallographic investigations of urinary calcium oxalate calculi

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Citrate in urine and serum and associated variables in subgroups of urolithiasis. Results from an outpatient stone clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

THE RELATION OF URINARY CITRIC ACID EXCRETION TO THE MENSTRUAL CYCLE AND THE STEROIDAL REPRODUCTIVE HORMONES

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Concretions and methylene blue.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Placebo versus allopurinol for renal calculi

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

The possible use of methylene blue in the treatment of primary hyperoxaluria

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Calcium oxalate crystal growth in normal urine: role of contraceptive hormones

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

The Influence of Refined Carbohydrate on Urinary Calcium Excretion

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

The dissolution of calcium oxalate kidney stones. A kinetic study

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Calcium clearance as a function of sodium clearance in the dog

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Oral methylene blue and the dissolution of renal calculi

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

Renal tubular transport of organic acids. Studies with oxalate and para-aminohippurate in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

1 reference

7 January 2021

Some factors influencing the urinary excretion of oxalic acid in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-5616%2886%2950008-5

7 January 2021

10.1016/S0195-5616(86)50008-5

Identifiers

DOI

1 reference

14 September 2017

1 reference